omeprazole has been researched along with Cystinosis in 2 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Cystinosis: A metabolic disease characterized by the defective transport of CYSTINE across the lysosomal membrane due to mutation of a membrane protein cystinosin. This results in cystine accumulation and crystallization in the cells causing widespread tissue damage. In the KIDNEY, nephropathic cystinosis is a common cause of RENAL FANCONI SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "GI symptoms in children with cystinosis receiving cysteamine are often acid-mediated and improve with omeprazole." | 7.72 | The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. ( Deutsch, R; Dohil, R; Newbury, RO; Schneider, JA; Sellers, ZM, 2003) |
| "Omeprazole is a proton pump inhibitor that inhibits gastric acid secretion and, theoretically, may cause the premature release of cysteamine by increasing intragastric pH, thereby affecting the PK of CBDR." | 6.87 | A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis. ( Armas, D; Brannagan, M; Checani, GC; Confer, NF; Holt, RJ; Obaidi, M; Xie, Y, 2018) |
| "GI symptoms in children with cystinosis receiving cysteamine are often acid-mediated and improve with omeprazole." | 3.72 | The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. ( Deutsch, R; Dohil, R; Newbury, RO; Schneider, JA; Sellers, ZM, 2003) |
| "Omeprazole is a proton pump inhibitor that inhibits gastric acid secretion and, theoretically, may cause the premature release of cysteamine by increasing intragastric pH, thereby affecting the PK of CBDR." | 2.87 | A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis. ( Armas, D; Brannagan, M; Checani, GC; Confer, NF; Holt, RJ; Obaidi, M; Xie, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armas, D | 1 |
| Holt, RJ | 1 |
| Confer, NF | 1 |
| Checani, GC | 1 |
| Obaidi, M | 1 |
| Xie, Y | 1 |
| Brannagan, M | 1 |
| Dohil, R | 1 |
| Newbury, RO | 1 |
| Sellers, ZM | 1 |
| Deutsch, R | 1 |
| Schneider, JA | 1 |
1 trial available for omeprazole and Cystinosis
| Article | Year |
|---|---|
A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
Topics: Administration, Oral; Adolescent; Adult; Citrus sinensis; Cysteamine; Cystine Depleting Agents; Cyst | 2018 |
1 other study available for omeprazole and Cystinosis
| Article | Year |
|---|---|
The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine.
Topics: Anti-Ulcer Agents; Child; Child, Preschool; Cysteamine; Cystinosis; Female; Gastric Acid; Gastrins; | 2003 |